Pablo Tebas

faculty photo
Professor of Medicine at the Hospital of the University of Pennsylvania
Attending Physician, Hospital of the University of Pennsylvania
Director & Principal Investigator, AIDS Clinical Trial Unit (ACTU) research site, University of Pennsylvania
Investigator of the Vaccine Trials Network, University of Pennsylvania
Director, Developmental Core Center for AIDS research (CFAR), Perelman School of Medicine, University of Pennsylvania
Department: Medicine

Contact information
Academic Address: 502 Johnson Pavilion
Clinical Office: 4 Perelman Center for Advanced Medicine, 3600 Civic Center Boulevard
Philadelphia, PA 19104
Office: 215-349-8092
Fax: 215-349-8011
Education:
MD
Universidad Autónoma de Madrid, Spain, 1985.
Permanent link
 

Description of Research Expertise

My research interests center around the study of the complications of HIV and its treatment, and currently in the evaluation of strategies for the cure of HIV infection.
I am the director and the PI of the AIDS clinical trial unit of the University of Pennsylvania.
I am one of the founding members of the HIV Reservoirs and Viral Eradication (Cure) Transformative Science Group (TSG) of the AIDS clinical trial group. In addition to my ACTG work, I am involved (as PI of the clinical project) in several early phase trials of new compounds developed in conjunction with the NIH in several IPCP grants, including a Phase I study evaluating the antiviral activity of aprepitant (an NK-1R antagonist that down-regulates the expression of CCR5), a phase I study evaluating the immunogenicity of a therapeutic DNA vaccine administered by intramuscular electroporation in collaboration with David Weiner and several gene therapy studies evaluating the therapeutic use of lentiviral vectors in the management of HIV infection (including the use of VIRxSYS 496 –antisense approach-, the first in humans Sangamo’s zinc finger nuclease for CCR5 edition, in collaboration with Dr. Carl June.

Description of Itmat Expertise

Dr. Tebas is involved in clinical trials evaluating new therapies for HIV infection including gene therapy and therapeutic DNA vaccines. His research interests include antiretroviral therapy, treatment of virologic failures, simplification strategies as well studying the metabolic complications associated with antiretroviral treatment.

Selected Publications

Bedimo, R. J., Adams-Huet, B., Poindexter, J., Brown, G., Farukhi, I., Castanon, R., Turner, D., Moore, T., Tebas, P., Maalouf, N. M.: The Differential Effects of HIV and HCV on Bone Micro-Architecture and Fracture risk. Clin Infect Dis November 2017.

George, V., Harrison, L., Roach, M., Li, X. D., Tierney, C., Fischl, M. A., Aberg, J., Tebas, P., Asmuth, D. M., Pollard, R. B., Godfrey, C., Pahwa, S., Aids Clinical Trials Group A Study Team: Associations of Plasma Cytokine and Microbial Translocation Biomarkers With Immune Reconstitution Inflammatory Syndrome. J Infect Dis October 2017.

Tebas, P., Roberts, C. C., Muthumani, K., Reuschel, E. L., Kudchodkar, S. B., Zaidi, F. I., White, S., Khan, A. S., Racine, T., Choi, H., Boyer, J., Park, Y. K., Trottier, S., Remigio, C., Krieger, D., Spruill, S. E., Bagarazzi, M., Kobinger, G. P., Weiner, D. B., Maslow, J. N.: Safety and Immunogenicity of an Anti-Zika Virus DNA Vaccine - Preliminary Report. N Engl J Med October 2017.

Gallant J, Lazzarin A, Mills A, Orkin C, Podzamczer D, Tebas P, Girard PM, Brar I, Daar ES, Wohl D, Rockstroh J, Wei X, Custodio J, White K, Martin H, Cheng A, Quirk E: Bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir, abacavir, and lamivudine for initial treatment of HIV-1 infection (GS-US-380-1489): a double-blind, multicentre, phase 3, randomised controlled non-inferiority trial. Lancet 36(17): 32299-7, Sep 2017.

Kelly, B. J., Tebas, P.: Clinical Practice and Infrastructure Review of Fecal Microbiota Transplantation for Clostridium difficile Infection. Chest September 2017.

Herati RS, Muselman A, Vella L, Bengsch B, Parkhouse K, Del Alcazar D, Kotzin J, Doyle SA, Tebas P, Hensley SE, Su LF, Schmader KE, Wherry EJ: Successive annual influenza vaccination induces a recurrent oligoclonotypic memory response in circulating T follicular helper cells. Sci Immunol 2(8), Aug 2017.

Yin, M. T., Chan, E. S., Brown, T. T., Tebas, P., McComsey, G. A., Melbourne, K., Napoli, A., Hardin, R., Ribaudo, H. J., Overton, E. T., A. Study Team: Racial differences in calculated bioavailable vitamin D with vitamin D/calcium supplementation: ACTG A5280. AIDS August 2017.

Koenig HC, Mounzer K, Daughtridge GW, Sloan CE, Lalley-Chareczko L, Moorthy GS, Conyngham SC, Zuppa AF, Montaner LJ, Tebas P: Urine assay for tenofovir to monitor adherence in real time to tenofovir disoproxil fumarate/emtricitabine as pre-exposure prophylaxis. HIV Med 18(6): 412-418, June 2017.

Beigel, J. H., Tebas, P., Elie-Turenne, M. C., Bajwa, E., Bell, T. E., Cairns, C. B., Shoham, S., Deville, J. G., Feucht, E., Feinberg, J., Luke, T., Raviprakash, K., Danko, J., O'Neil, D., Metcalf, J. A., King, K., Burgess, T. H., Aga, E., Lane, H. C., Hughes, M. D., Davey, R. T., I. R. C. Study Team: Immune plasma for the treatment of severe influenza: an open-label, multicentre, phase 2 randomised study. Lancet Respir Med 5(6): 500-511, June 2017.

Drechsler, H., Ayers, C., Cutrell, J., Maalouf, N., Tebas, P., Bedimo, R.: Current use of statins reduces risk of HIV rebound on suppressive HAART. PLoS One 12(3): e0172175, March 2017.

back to top
Last updated: 11/27/2017
The Trustees of the University of Pennsylvania